Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 m RNA in human foetal and adult brain by in situ hybridization

References

• ARORA, P. K., RIACHI, N. J., HAIUK, S. I. and SAYRE, L. M., 1988, Chemical oxidation of 1-methyl- 4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) and its in vivo metabolism in rat brain and liver. Biochemical and Biophysical Research Communication. 15Z 1339–1347.
   Web of Science ®Google Scholar
• BALLARD, P. A., TEIRW, J. W. and LANGSTON, J. W., 1985, Permanent human parkinsonism due to 1- methyl- 4-pheny1-1,2,3,6- tetrahydropyridine (MPTP) : seven cases. Neurology, 35, 949–956.
   PubMed Web of Science ®Google Scholar
• BARBEAU, A., CLOUTIER, T., ROY, M., PLASSE, L., PARIS, S. and POIRER, J., 1987, Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet, II, 1213–1216.
   Google Scholar
• BERTILSSON, L., ALm, D., DE LAS CARRERAS, C., Wrossr, J., EDMAN, G. and SCHALLING, D., 1989, Debrisoquine hydroxylation and personality. Lancet, II, 555.
   Google Scholar
• BORLAK, J. T., HARSANY, V., SCHNEBLE, H. and HAEGELE, K. D., 1994, pNAT and CYP2D6 gene polymorphism in epileptic patients. Biochemical Pharmacology, 48, 1717–1720.
   PubMed Web of Science ®Google Scholar
• CASHMAN, J. R. and ZIEGLER, D. M., 1985, Contribution of N-oxygenation to the metabolism of MPTP (1-methyl- 4-phenyl- 1,2,3,6- tetrahydropyridine) by various liver preparations. Molecular Phar-macology, 29, 163–167.
   Web of Science ®Google Scholar
• CHIBA, K., KUBOTA, E., MIYAKAWA, T., KATO, Y. and IsruzArc, T., 1988, Characterization of hepatic microsomal metabolism as an in vivo detoxification pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Journal of Pharmacology and Experimental Therapeutics, 246, 1108–1115.
   PubMed Web of Science ®Google Scholar
• COLEMAN, T., aus, S. W., MARTIN, I. J., LENNARD, M. S. and TUC, G. T., 1996, 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 277, 685–690.
   PubMed Web of Science ®Google Scholar
• FONNE -PFISTER, R, BARGETZI, M. J. and MEYER, U. A., 1987, MPTP, the neurotoxin inducing Parkinson's Disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufT, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochemical and Biophysical Research Communication. 148, 1144–1150.
   Google Scholar
• FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. W., Sr, P. and Wow, C. R., 1992, Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359–368.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J., SKODA, R. C., KIMURA, S., UMENO, M., ZANGER, U. M., NEBERT, D. W., GELBOIN H. V., HARDWICK, J. P. and MEYER, U. A., 1988, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442–446.
   Google Scholar
• GOUGH, A. C., MILES, J. S., Moss, J. E., GAEDIGK, A., EICHELBAUM, M. and WOLF, C. R., 1990, Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347, 773–776.
   PubMed Web of Science ®Google Scholar
• GUT, J., CATIN, T., DAYER, P., KRONBACH, T., ZANGER, U. and MEYER, U. A., 1986, Debrisoquinei sparteine- type polymorphism of drug oxidation. Journal of Biological Chemistry, 26, 11734–11743.
   Google Scholar
• HAGLUND, L., KOHLER, C., HAAPARANTA, T., GOLDSTEIN, M. and GUSTAFSSON, J. A., 1984, Presence of NADPH- cytochrome P450 reductase in central catecholaminergic neurones. Nature, 307, 259–262.
   PubMed Web of Science ®Google Scholar
• HAYES, J. D. and WOLF, C. R., 1990, Molecular mechanisms of drug resistance. BiochernicalJoumal, 272 281–295.
   Google Scholar
• JIMENEZ -JIMENEZ, F. J., T ABERNERO, C., MENA, M. A., GARCIA DE YEBENES, J., GARCIA DE YEBENES M. J., CASAREJOS, M. J., PARDO, B., GARCIA-AGUNDEZ, J. A., BENITEZ, J., MARTINEZ, A. and GARCIA-ASENTO, J. A. L., 1991, Acute effects of 1-methyl- 4-phenyl- 1,2,3,6- tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. Journal of Neurochemistry, 57, 81–87.
   Google Scholar
• KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatography assays for bufuralol 1 '-hydroxylase, debrisoquine 4'-hydroxylase, and dextro-methorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry, 162 24–32.
   PubMed Web of Science ®Google Scholar
• KUTTY,, R. K., SANTOSTASI, G., HORNG, J. and KRISHNA, G., 1991, MPTP- induced ATP depletion and cell death in neuroblastoma xglioma hybrid NG 108-15 cells: protection by glucose and sensitization by tetraphenylborate. Toxicology and Applied Pharmacology, 107, 377–388.
   PubMed Web of Science ®Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MODI, S., PAINE, M. J., SUTCLIFFE, M. J., LIAN, L.-Y., PRIMROSE, W. U., WOLF, C. R. and ROBERTS, G. C. K., 1996, Substrate binding to cytochrome P450 2D6. Biochemistry, 35, 4540–4550.
   Google Scholar
• MOLDEUS, P., HOGBERG, J. and ORRENIU S., 1978, Isolation and use of liver cells. Methods in Enzymology, LH, part C, 60–71.
   Google Scholar
• NIZIK, H. B., TYNDALE, R. F., SALLEE, H. R., GONZALEZ, F. J., HARDWICK, J. P., INABA, T. and KALOW, K., 1990, The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [I] GBR-12935 binding sites. Archives of Biochemistry and Biophysics, 276, 424–432.
   PubMed Web of Science ®Google Scholar
• PAI, K. S. and RAVINDRANATH, V., 1991, Protection and potentiation of MPTP- induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices. Brain Research, 555, 239–244.
   PubMed Web of Science ®Google Scholar
• PAINE, M. J. I., GILHAM, D., ROBERTS, G. C. K. and WOLF, C. R., 1996, Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems. Archives of Biochemistry and Biophysics, 328, 143–150.
   Google Scholar
• POIRER, J., ROY, M., CAMPANELLA, G., CLOUTIER, T. and PARI S., 1987, Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet, ii, 386.
   Google Scholar
• PRICE-EVANS, D. A., MAHGOUB, A., SLOAN, T. P., IDLE, J. R. and Swill, R. L., 1980, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics, 17, 102–105.
   Google Scholar
• SALACH, J. I., SINGER, T. P., CASTAGNOLI, JR, N. and TREVOR, A., 1984, Oxidation of the neurotoxic amine 1-mehty1-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochemical and Biophysical Research Communication. 125, 831–835.
   Google Scholar
• SENIOR, P. V., CREIUHLEY, D. R., BECK, F., WALKER, R. A. and VARLEY, J. M., 1988, The localisation of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: an in situ hybridisation and immunohistochemical study. Development, 104, 431–446.
   PubMed Web of Science ®Google Scholar
• SHAHI, G. S., DAS, N. P. and MOOCHHALA, S. M., 1990, Parkinson's disease and cytochrome P450: a possible link? Medical Hypothesis, 32, 277–282.
   PubMed Web of Science ®Google Scholar
• SHINKA, T., CASTAGNOLI, JR. N., Wu, E. Y., HOAG, M. K. P. and TREVOR, A. J., 1987, Cation-exchange high performance liquid chromatography assay for the nigrostriatal oxicant 1-methyl- 4-phenyl-1,2,3,6- tetrahydropyridine and its monoamine oxidase B generated metabolites in brain tissues. Journal of Chromatography, 398, 279–287.
   Google Scholar
• SINDRUP, S. H., POULSEN, L., BROSEN, K., ARENDT -NIELSEN, L. and GRAM, L. F., 1993, Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers ? Pain, 537, 335–349.
   Google Scholar
• SMITH, C. A. D., GOUGH, A. C., LEIGH, P. N., SUMMERS, B. A., HARDING, A. E., MARANGANORE, D. M., STURMAN, S. G., SCHAPIRA, A. H. V., WILLIAMS, AC., S PURR, N. K. and WOLF, C. R., 1992, Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339, 1375–1377.
   Google Scholar
• SPENCER, P. S., LUDOLPH, A. C. and KISBY, G. E., 1993, Neurologic diseases associated with use of plant components with toxic potential. Environmental Research, 62, 106–113.
   PubMed Web of Science ®Google Scholar
• SUTCLIFFE, R. L. G. and MEARA, J. R., 1995, Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurologica Scandinavia, 92, 443–450.
   Google Scholar
• TANNER, C. M., 1991, Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. Neurology, 41 (suppl. 2), 89–91.
   PubMed Web of Science ®Google Scholar
• TIPTON, K. F., MCCRODDEN, J. M. and SULLIVAN, J. P., 1993, Metabolic aspects of the behavior of MPTP and some analogues. Advances in Neurology, 60, 186–192.
   PubMedGoogle Scholar
• TUCKER, G. T., 1994, Clinical implications of genetic polymorphism in drug metabolism. Journal of Pharmacy and Pharmacology, 46 (suppl. 1), 417–424.
   PubMed Web of Science ®Google Scholar
• TYNDALE, R. F., SUNAHARA, R., INABA, T., KALOW, W., GONZALEZ, F. J. and Nizm, H. B., 1991, Neuronal cytochrome P45011D1 (debrisoquine /sparteine- type): potent inhibition of activity by ( - )-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Molecular Pharmacology, 40, 63–68.
   PubMed Web of Science ®Google Scholar
• WEISSMAN, J., T REVOR, A., CHB3A, K., PETERSON, L. A., CALDERA, P., CASTANOLI, JR, N. and BAILLIE, T., 1985, Metabolism of the nigrostriatal toxin 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine by liver homogenate fractions. Journal of Medicinal Chemistry, 28, 997–1001.
   Google Scholar
• WOLF, C. R., 1990, Metabolic factors in cancer susceptibility. Cancer Surveys, 9, 437–474.
   PubMedGoogle Scholar
• ZANDVLIET, D. W. J., HANBY, A. M., AusTrN, C. A., MARSH, K. L., CLARK, I. B. N., WRIGHT, N. A. and PouLsom, R., 1996, Analysis of foetal expression sites of human type II DNA topoisomerase a and mRNAs by in situ hybridisation. Biochemical Biophysica Acta,1307, 239–247.
   Google Scholar